The DOI matches its Crossref record; 135 of the 137 references it cites were found in a registry or an index.
NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma
Open accessAbstract
Hepatic cirrhosis and hepatocellular carcinoma (HCC) are the most common causes of death in patients with chronic liver disease. Chronic liver injury of virtually any etiology triggers inflammatory and wound-healing responses that in the long run promote the development of hepatic fibrosis and HCC. Here, we review the role of the transcription factor nuclear factor-κB (NF-κB), a master regulator of inflammation and cell death, in the development of hepatocellular injury, liver fibrosis and HCC, with a particular focus on the role of NF-κB in different cellular compartments of the liver. We propose that NF-κB acts as a central link between hepatic injury, fibrosis and HCC, and that it may represent a target for the prevention or treatment of liver fibrosis and HCC. However, NF-κB acts as a two-edged sword and inhibition of NF-κB may not only exert beneficial effects but also negatively impact hepatocyte viability, especially when NF-κB inhibition is pronounced. Finding appropriate targets or identifying drugs that either exert only a moderate effect on NF-κB activity or that can be specifically delivered to nonparenchymal cells will be essential to avoid the increase in liver injury associated with complete NF-κB blockade in hepatocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the decisive factor is that NF-κB-activation additionally causes a significantly increased resistance against apoptosis in aHSCs.[21]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Phosphorylation meets ubiquitination: the control of NF-κB activity
Karin, M., & Ben-Neriah, Y. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.621 · Cited by 4,766
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727
TLR4 links innate immunity and fatty acid-induced insulin resistance
Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I., Yin, H., & Flier, J. S. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28898 · Cited by 3,690
Missing Pieces in the NF-κB Puzzle
Ghosh, S., & Karin, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00703-1 · Cited by 3,638
Activators and Target Genes of Rel/NF-кB Transcription Factors
Loop, T., & Pahl, H. L. (2003) · Springer eBooks · doi:10.1007/978-94-010-0163-2_1 · Cited by 3,179
An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death
Beg, A. A., & Baltimore, D. (1996) · Science · doi:10.1126/science.274.5288.782 · Cited by 3,047
Cited by
Sorted by citations
Items 601–700 of 999
Chen, P., Wang, R., Liu, F., Li, S., Gu, Y., Wang, L., & Yuan, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1092151 · Cited by 23
Ismail, S. A., Mayah, W. W., Battia, H. E., Gaballah, H. H., Jiman-Fatani, A. A., Hamouda, H., Afifi, M. A. E., Elmashad, N. M., & Saadany, S. A. E. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.4.1657 · Cited by 22
Wang, T., Xia, L., Ma, S., Qi, X., Li, Q., Xia, Y. F., Tang, X., Cui, D., Wang, Z., Chi, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25183 · Cited by 22
Prebiotics: A Novel Approach to Treat Hepatocellular Carcinoma
Fatima, N., Akhtar, T., & Sheikh, N. (2017) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2017/6238106 · Cited by 22
Yu‐Wai‐Man, C., Owen, N., Lees, J., Tagalakis, A. D., Hart, S. L., Webster, A. R., Orengo, C. A., & Khaw, P. T. (2017) · Scientific Reports · doi:10.1038/s41598-017-05780-5 · Cited by 22
Strowitzki, M. J., Kirchberg, J., Tuffs, C., Schiedeck, M., Ritter, A. S., Biller, M., Harnoss, J. M., Lasitschka, F., Schmidt, T., Radhakrishnan, P., et al. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.08.003 · Cited by 21
Oncogenic role of phospholipase C‐γ1 in progression of hepatocellular carcinoma
Tang, W., Zhou, Y., Sun, D., Dong, L., Xia, J., & Yang, B. (2019) · Hepatology Research · doi:10.1111/hepr.13309 · Cited by 22
Dimethylfumarate ameliorates hepatic injury and fibrosis induced by carbon tetrachloride
Mostafa, M., Shaaban, A. A., & Salem, H. A. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.01.029 · Cited by 22
Ramos‐Tovar, E., Flores‐Beltrán, R. E., Galindo‐Gómez, S., Camacho, J., Tsutsumi, V., & Muriel, P. (2019) · Annals of Hepatology · doi:10.1016/j.aohep.2018.10.002 · Cited by 22
Koo, B.-W., Lim, D.-J., Oh, A., & Na, H. (2020) · Medical Principles and Practice · doi:10.1159/000506637 · Cited by 22
Kim, J. K., Han, N. R., Park, S. M., Jegal, K. H., Jung, J. Y., Jung, E. H., Kim, E. O., Kim, D., Jung, D. H., Lee, J. R., et al. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.111044 · Cited by 22
Targeting thrombospondin-2 retards liver fibrosis by inhibiting TLR4-FAK/TGF-β signaling
Zhang, N., Wu, X., Zhang, W., Sun, Y., Yan, X., Xu, A., Han, Q., Yang, A., You, H., & Chen, W. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101014 · Cited by 22
Galicia‐Moreno, M., Monroy-Ramírez, H. C., Caloca-Camarena, F., Arceo-Orozco, S., Muriel, P., Sandoval-Rodriguez, A. S., Garcia-Bañuelos, J. J., García, A., Navarro‐Partida, J., & Armendáriz‐Borunda, J. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03539-0 · Cited by 22
Yuan, H., Liu, J., Xu, R., Yang, K., Qu, R., Liu, S., Zhang, Y., & Xiang, M. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00745-3 · Cited by 21
Castven, D., Fischer, M., Becker, D., Heinrich, S., Andersen, J. B., Strand, D. J., Sprinzl, M. F., Strand, S., Czauderna, C., Heilmann‐Heimbach, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16231 · Cited by 21
RelB promotes liver fibrosis via inducing the release of injury‐associated inflammatory cytokines
Zhou, D., Huang, W., Wei, J., Zhang, J., Liu, Z., Ji, R., Ge, S., Xiao, M., Fan, Y., & Lu, C. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15108 · Cited by 21
Nakamura, R., Mukudai, S., Bing, R., Garabedian, M. J., & Branski, R. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-77445-9 · Cited by 21
Gupta, M., Krishan, P., Kaur, A., Arora, S., Trehanpati, N., Singh, T. G., & Bedi, O. (2021) · Inflammation Research · doi:10.1007/s00011-021-01480-z · Cited by 21
Srivastava, A., Sharma, H., Khanna, S., Balasundaram, T. S., Chowdhury, S., Chowdhury, R., & Mukherjee, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.811941 · Cited by 21
Lin, X., Wei, Y., Li, Y., Xiong, Y., Fang, B., Li, C., Huang, Q., Huang, R., & Wei, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.801982 · Cited by 21
Cordycepin Protects against Hepatic Ischemia/Reperfusion Injury via Inhibiting MAPK/NF-κB Pathway
Ding, J., WenjuanYang, Jiang, Y., Ji, J., Zhang, J., Wu, L., Feng, J., Zheng, Y., Li, Y., Cheng, Z., et al. (2022) · Mediators of Inflammation · doi:10.1155/2022/5676256 · Cited by 21
AbuBakr, N., Fares, A. E., Mostafa, A., & Farag, D. B. E. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e10857 · Cited by 21
Endoplasmic reticulum stress in the pathogenesis of alcoholic liver disease
Na, M., Yang, X., Deng, Y., Yin, Z., & Li, M. (2023) · PeerJ · doi:10.7717/peerj.16398 · Cited by 23
Edwards, H., Javed, K., Yadev, K., Ara, C., & Omer, A.-M. (2024) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2024.105966 · Cited by 22
Spontaneous and transgenic rodent models of inflammatory bowel disease
Prattis, S. M., & Jurjus, A. R. (2015) · Laboratory Animal Research · doi:10.5625/lar.2015.31.2.47 · Cited by 22
A cell-type-specific role for murine Commd1 in liver inflammation
Bartuzi, P., Wijshake, T., Dekker, D., Fedoseienko, A., Kloosterhuis, N., Youssef, S. A., Li, H., Shiri‐Sverdlov, R., Kuivenhoven, J. A., de Bruin, A., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.035 · Cited by 20
Hassan, M. H., & Ghobara, M. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1263-1 · Cited by 21
Novel chemokine-like activities of histones in tumor metastasis
Chen, R., Xie, Y., Zhong, X. Y., Fu, Y., Huang, Y., Zhen, Y., Pan, P., Wang, H., Bartlett, D. L., Billiar, T. R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11226 · Cited by 21
Pinna, F., Bissinger, M., Beuke, K., Huber, N., Longerich, T., Kummer, U., Schirmacher, P., Sahle, S., & Breuhahn, K. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00610 · Cited by 21
n-3 PUFAs reduce tumor load and improve survival in a NASH-tumor mouse model
Liebig, M., Dannenberger, D., Vollmar, B., & Abshagen, K. (2019) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319872118 · Cited by 22
Kaushal, N., Gupta, M., & Kulshreshtha, E. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e04422 · Cited by 21
Research Progress on Natural Products Alleviating Liver Inflammation and Fibrosis via NF‐κB Pathway
Li, X., Li, S., & Li, N. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202402248 · Cited by 22
Qi, Y., Fu, Y., Wu, X., Chen, Z., Tang, Y., Ao, H., Zhu, H., Zou, C., Sun, B., Zheng, C., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c11552 · Cited by 23
Matsushita, J., Okamura, K., Nakabayashi, K., Suzuki, T., Horibe, Y., Kawai, T., Sakurai, T., Yamashita, S., Higami, Y., Ichihara, G., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4221-0 · Cited by 20
Green tea extract inhibits early oncogenic responses in mice with nonalcoholic steatohepatitis
Dey, P., Kim, J. B., Chitchumroonchokchai, C., Li, J., Sasaki, G. Y., Olmstead, B. D., Stock, K. L., Thomas‐Ahner, J. M., Clinton, S. K., & Bruno, R. S. (2019) · Food & Function · doi:10.1039/c9fo01199d · Cited by 20
Spinelli, G., Biddeci, G., Artale, A., Valentino, F., Tarantino, G., Gallo, G., Gianguzza, F., Conaldi, P. G., Corrao, S., Gervasi, F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-02119-z · Cited by 21
Hepatoprotective Role of 4-Octyl Itaconate in Concanavalin A-Induced Autoimmune Hepatitis
Yang, W., Wang, Y., Zhang, P., Wang, T., Li, C., Tong, X., Zeng, X., Yin, Y., Tao, K., & Li, R. (2022) · Mediators of Inflammation · doi:10.1155/2022/5766434 · Cited by 20
Li, J., Chang, J., Wang, J., Xu, D., Yang, M., Jiang, Y., Zhang, J., Jiang, X., & Sun, Y. (2022) · Carcinogenesis · doi:10.1093/carcin/bgac042 · Cited by 20
Yu, S., Long, Y., Li, D., Shi, A., Deng, J., Ma, Y., Wen, J., Li, X., Zhang, Y., Liu, S., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106339 · Cited by 21
Zhang, Y., Hua, L., Lin, C., Yuan, M., Xu, W., Anand Raj, D., Venkidasamy, B., Céspedes, C. L., Nile, S. H., Yan, G., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.937484 · Cited by 22
Peptide‐Based Nanoarchitectonics for the Treatment of Liver Fibrosis
Li, B., Huang, Y., & Zou, Q. (2023) · ChemBioChem · doi:10.1002/cbic.202300002 · Cited by 22
Ament, C. E., Steinmann, S. M., Evert, K., Pes, G. M., Ribback, S., Gigante, I., Pizzuto, E., Bañales, J. M., Rodrigues, P. M., Olaizola, P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000322 · Cited by 20
Wang, L. X., Zhu, J., Xie, P., & Gong, D. (2023) · Life · doi:10.3390/life13091866 · Cited by 20
Elzainy, A., Sadik, A. E., & Altowayan, W. M. (2024) · Biomolecules · doi:10.3390/biom14030297 · Cited by 19
Yao, Y., Zuo, X., Shao, F., Yu, K., & Liang, Q. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155502 · Cited by 21
Wang, R., Mi, H.-M., Li, H., Zhao, S.-X., Yan-hong, J. I. A., & Nan, Y. (2015) · Europe PMC (PubMed Central) · Cited by 20
Li, C. X., Lo, C. M., Lian, Q., Ng, T., Liu, X. B., Yuen, Y., Qi, X., Yeung, O. W. H., Tergaonkar, V., Yang, X. X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8509 · Cited by 20
Fang, S., Yuan, J., Shi, Q., Xu, T., Fu, Y. S., Wu, Z., & Guo, W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174374 · Cited by 20
Wan, L., Shen, J., Wang, Y., Zhao, W., Fang, N., Yuan, X., & Xue, B. (2019) · Scientific Reports · doi:10.1038/s41598-018-38391-9 · Cited by 20
Mahmoud, N. I., Messiha, B. A. S., Salehc, I. G., Abo‐Saif, A. A., & Abdel‐Bakky, M. S. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.078 · Cited by 20
Li, Z., Wang, H., Zeng, Q., Yan, J., Hu, Y., Li, H., & Yu, Z. (2020) · Cancer Medicine · doi:10.1002/cam4.2611 · Cited by 20
Zhou, Y., Liu, Z., Lynch, E. C., He, L., Cheng, H., Liu, L., Li, Z., Li, J., Lawless, L., Zhang, K. K., et al. (2020) · Laboratory Investigation · doi:10.1038/s41374-020-00493-2 · Cited by 20
Givinostat inhibition of hepatic stellate cell proliferation and protein acetylation
Wang, Y. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i27.8326 · Cited by 20
miR-3117 regulates hepatocellular carcinoma cell proliferation by targeting PHLPPL
Cui, X., Li, Q., & He, Y. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2855-2 · Cited by 19
Wan, Z., Li, H., Wu, X., Zhao, H., Wang, R., Li, M., Liu, J., Liu, Q., Wang, R., & Li, X. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118689 · Cited by 19
El‐Gendy, Z. A., El‐Marasy, S. A., Ahmed, R. F., El‐Batran, S., El‐Rahman, S. S. A., Ramadan, A. E., & Youssef, S. A. H. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e07159 · Cited by 19
Zhu, D., Tan, X., Lu, L., Yu, S., Jian, R.-L., Liang, X., Liao, Y.-X., Fan, W., Barbier-Torres, L., Yang, A., et al. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i22.2944 · Cited by 19
Pekmezci, A. K., Çakıroğlu, E., Eris, S., Mazi, F. A., Coskun-Deniz, O. S., Dalgıç, E., Öz, Ö., & Şentürk, Ş. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121690 · Cited by 19
RAGE pathways play an important role in regulation of organ fibrosis
Liu, J., Jin, Z., Wang, X., Jakoš, T., Zhu, J., & Yuan, Y. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121713 · Cited by 20
Mangiferin for the Management of Liver Diseases: A Review
Li, L., Dong, Y., Liu, X., & Wang, M. (2023) · Foods · doi:10.3390/foods12132469 · Cited by 21
Jiang, C., Zhang, C., Dai, M., Wang, F., Xu, S., Han, D., Wang, Y., Cao, Y.-J., Liang, Y., Zhang, Z., et al. (2023) · Biochimica et biophysica acta. Molecular cell research · doi:10.1016/j.bbamcr.2023.119595 · Cited by 17
Yao, L., Cai, H., Fang, Q., Liu, D., Zhan, M., Chen, L., & Du, J. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176149 · Cited by 19
Xiang, M., Su, H., Hu, Y., Hu, Y. F., Yang, T., & Shu, G. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.09.008 · Cited by 19
Qian, J., Luo, Y., Gu, X., & Wang, X. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1288 · Cited by 19
A novel player in inflammation and cancer: The deubiquitinase CYLD controls HCC development
Gautheron, J., & Luedde, T. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.039 · Cited by 19
Self-citationBML-111 equilibrated ACE-AngII-AT1R and ACE2-Ang-(1-7)-Mas axis to protect hepatic fibrosis in rats
Hu, Q.-D., Hu, Z., Chen, Q., Huang, Y., Mao, Z., Xu, F., & Zhou, X. (2017) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2017.08.008 · Cited by 19
Fayed, M. R., El‐Naga, R. N., Akool, E., & El‐Demerdash, E. (2018) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2017.01065 · Cited by 19
Fang, Q., Shen, Q., Li, J., Yang, Y., Guo, J., Cheng, Y., Zhou, H., Niu, W., Chen, L., Li, C., et al. (2019) · Hepatology Research · doi:10.1111/hepr.13330 · Cited by 20
Tommasi, S., Yoon, J., & Nia, A. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041296 · Cited by 19
Impaired Bile Secretion Promotes Hepatobiliary Injury in Sickle Cell Disease
Vats, R., Liu, S., Zhu, J., Mukhi, D., Tütüncüoğlu, E., Cárdenes, N., Singh, S., Brzóska, T., Kosar, K., Bamne, M. N., et al. (2020) · Hepatology · doi:10.1002/hep.31239 · Cited by 20
Lee, S. R., Lee, J. G., Heo, J. H., Jo, S. L., Ryu, J., Kim, G., Yon, J., Lee, M. S., Lee, G., An, B.-S., et al. (2021) · Cancers · doi:10.3390/cancers13102438 · Cited by 19
Alsuhaymi, N., Alsugoor, M. H., Shokry, A. A., Fayed, H. M., Mohamed, B. M. S. A., Afifi, S. M., Esatbeyoglu, T., Korany, R. M. S., & Elbaset, M. A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1586231 · Cited by 20
Pathogenesis of Hepatocellular Carcinoma Development in Non-alcoholic Fatty Liver Disease
Shetty, K., Chen, J., Shin, J., Jogunoori, W. S., & Mishra, L. (2015) · Current Hepatology Reports · doi:10.1007/s11901-015-0260-z · Cited by 18
Qian, H., & Chen, L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112340 · Cited by 18
Vukotić, M., Kapor, S., Dragojević, T., Đikić, D., Ajtić, O. M., Diklić, M., Subotički, T., Živković, E., Čokić, B. B., Vojvodić, A., et al. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00742-y · Cited by 18
Crosstalk Between Autophagy and Innate Immunity: A Pivotal Role in Hepatic Fibrosis
Chen, L., Kong, D., Xia, S., Wang, F., Li, Z., Zhang, F., & Zheng, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.891069 · Cited by 18
Alshehade, S. A., Zarzour, R. H. A., Murugaiyah, V., Lim, S. Y. M., El-Refae, H. G., & Alshawsh, M. A. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.09.001 · Cited by 18
Jouve, M., Carpentier, R., Kraiem, S., Legrand, N., & Sobolewski, C. (2023) · Cancers · doi:10.3390/cancers15235557 · Cited by 18
Ou, K., Weng, C.-C., Sugiatno, E., Ruslin, M., Lin, Y., & Cheng, H. (2015) · Surgical Endoscopy · doi:10.1007/s00464-015-4596-9 · Cited by 18
Therapeutic potential of phages in autoimmune liver diseases
Górski, A., Jończyk‐Matysiak, E., Łusiak-Szelachowska, M., Weber‐Dąbrowska, B., Międzybrodzki, R., & Borysowski, J. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.13092 · Cited by 18
Yokoyama, T., Mendoza, H. Y., Tanaka, T., Ii, H., Takano, R., Yaegaki, K., & Ishikawa, H. (2019) · Human Cell · doi:10.1007/s13577-018-00234-0 · Cited by 19
Adel, N., Mantawy, E. M., Elsherbiny, D. A., & El‐Demerdash, E. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114748 · Cited by 19
Hussain, F., Basu, S., Heng, J. J. H., Loo, L., & Zink, D. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02778-3 · Cited by 21
Li, Y., Teng, L., Zhou, D., Wei, J., Li, Z., Li, X., Jia, S., Ouyang, Q., Qi, S., Chen, Z., et al. (2021) · Cell Adhesion & Migration · doi:10.1080/19336918.2021.1958441 · Cited by 18
Signal Transduction and Molecular Regulation in Fatty Liver Disease
Dong, X. C., Chowdhury, K., Huang, M., & Kim, H.-G. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0076 · Cited by 18
Diet-Regulating Microbiota and Host Immune System in Liver Disease
Eom, J. A., Kwon, G.-H., Kim, N. Y., Park, E. J., Won, S. M., Jeong, J., Ganesan, R., Gupta, H., Gebru, Y. A., Sharma, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126326 · Cited by 18
Ren, L., Li, J., Liu, L., Wu, W., Zhao, D., Zhang, K., Xin, X., Yang, L., & Yin, L. (2021) · Biomaterials Science · doi:10.1039/d1bm01499d · Cited by 19
Huang, S.-C., Kuo, P., Hung, H., Pan, T., Chen, F., & Wu, T.-S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050681 · Cited by 18
Tax1BP1 limits hepatic inflammation and reduces experimental hepatocarcinogenesis
Waidmann, O., Pleli, T., Weigert, A., Imelmann, E., Kakoschky, B., Schmithals, C., Döring, C., Frank, M., Longerich, T., Köberle, V., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73387-4 · Cited by 17
Jiang, Z., Liu, L., Su, H., Cao, Y., Ma, Z., Gao, Y., & Huang, D. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155234 · Cited by 18
Lee, I., Lee, S., Ko, J., Park, S.-H., Shin, I., Moon, C., Kim, S., & Kim, J.-C. (2016) · Laboratory Animal Research · doi:10.5625/lar.2016.32.1.24 · Cited by 17
Xiong, Y., Wen, S., Li, Y., Wei, Y., Fang, B., Li, C., Huang, Q., & Lin, X. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174770 · Cited by 18
Ke, C., Gao, J., Tu, J., Wang, Y., Xiao, Y., Wu, Y. S., Liu, Y., & Zhou, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.930785 · Cited by 17
Yun, H.-J., Suh, Y.-J., Kim, Y. B., Kang, E., Choi, J. H., Choi, J. H., Lee, I.-B., Choi, D., Seo, Y. J., Noh, J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214009 · Cited by 17
Cellular Factors Involved in the Hepatitis D Virus Life Cycle
Thiyagarajah, K., Basic, M., & Hildt, E. (2023) · Viruses · doi:10.3390/v15081687 · Cited by 17
Lycopene improves autophagy and attenuates carbon tetrachloride-induced hepatic fibrosis in rats
Li, W., Jiang, Y., Yu, T.-T., Hao, W., & Wang, G. (2023) · Croatian Medical Journal · doi:10.3325/cmj.2023.64.243 · Cited by 17
Cao, L. L., Zhou, Y., Lin, S., Yang, C., Guan, Z., Li, X., Yang, S., Gao, T., Zhao, J., Fan, N., et al. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12499 · Cited by 18
Antifibrosis Effect of Novel Oridonin Analog CYD0618 Via Suppression of the NF-κB Pathway
Cummins, C. B., Wang, X., Xu, J., Hughes, B. D., Ding, Y., Chen, H., Zhou, J., & Radhakrishnan, R. S. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.06.040 · Cited by 17
Zheng, X., Wu, J., Gong, Y., Hong, J., Xiao, H., Zhong, J., Xie, B., Li, B., Guo, G., Zhu, X., et al. (2018) · Immunology and Cell Biology · doi:10.1111/imcb.12207 · Cited by 17
Inflammasome as an Effective Platform for Fibrosis Therapy
Chen, T., Xiao, F., Li, N., Shan, S., Qi, M., Wang, Z., Zhang, S., Wei, W., & Sun, W. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s304180 · Cited by 17
Metadata
- Authors
- Luedde, T., & Schwabe, R. F.
- Affiliations
- Universitätsklinikum Aachen (DE)
- Columbia University Irving Medical Center (US)
- Corresponding author
- Luedde, Tom
- Schwabe, Robert F.
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2011-02
- Volume
- 8
- Issue
- 2
- Pages
- 108-118
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- PMC
- PMC3295539
- OpenAlex
- W1976777085
- Cited by
- 1,345
- References
- 137
- Citations by year
- 2026: 97 · 2025: 99 · 2024: 119 · 2023: 109 · 2022: 122 · 2021: 156 · 2020: 120 · 2019: 95 · 2018: 79 · 2017: 76 · 2016: 66 · 2015: 68 · 2014: 51 · 2013: 38 · 2012: 42
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5u54ca126513-03)
- National Institute on Alcohol Abuse and Alcoholism (R01AA020211)
- National Cancer Institute (U54 CA126513.)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK076920)
- National Center for Complementary and Integrative Health (R21AT003878)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- NF-κB, liver fibrosis, hepatocellular carcinoma, chronic liver disease, liver cirrhosis, chronic liver injury, liver inflammation, hepatocytes, non-parenchymal liver cells, NF-κB inhibition, hepatocyte viability
- MeSH terms
- Cell Survival, Fibrosis, Carcinoma, Hepatocellular, Homeostasis, Humans, Liver, Liver Neoplasms, NF-kappa B, Hepatocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
